Large-Scale Study Uncovers Cancer Cachexia Patterns
Researchers have developed a comprehensive atlas of cancer cachexia, a severe wasting syndrome that significantly impacts morbidity and mortality in cancer patients. By repurposing longitudinal clinicogenomic data from 52,236 patients at Memorial Sloan Kettering Cancer Center (MSK) between 2010 and 2024, the study, published on October 12, 2026, in Nature Medicine, provides an episode-resolved, multimodal understanding of the condition.
Cachexia Episodes Linked to Disease Progression and Outcomes
The study defined cachectic episodes based on consensus-defined weight loss and linked these events to patient outcomes, serology, and tumor genotypes. These cachectic episodes were found to cluster near periods of disease progression and were associated with poorer outcomes across nearly all cancer types. The research analyzed over 2 million body weight measurements and millions of blood test results, combined with treatment histories and tumor genetic profiles.
Consistent Serological and Genetic Signatures Identified
Across diverse malignancies, cachectic weight loss episodes exhibited a consistent serological signature, characterized by lower levels of albumin and hemoglobin, and higher levels of liver enzymes. Furthermore, numerous somatic tumor genotypes, including TP53 mutations, were associated with a higher frequency of cachectic episodes. This suggests a complex interplay between tumor biology and host response.
Predictive Model Developed for Cachexia Risk
Motivated by these findings, the researchers developed a multivariate model to predict the impending risk of cachectic weight loss in patients with lung, colorectal, and prostate cancer. This model was validated in an independent cohort of 5,785 patients from the Dana-Farber Cancer Institute. The study concludes that routine clinicogenomic data represent a scalable resource for advancing the understanding and management of cancer cachexia.
Understanding Cancer Cachexia
Cancer cachexia affects approximately half of all cancer patients, characterized by progressive, unintentional weight loss accompanied by muscle wasting. It is more than ordinary weight loss; the body breaks down its own muscle and fat for energy, a process not easily reversed by increased food intake. The condition makes treatment harder to tolerate, erodes quality of life, and is linked to worse outcomes.
💬 Comments (0)